Shiney Chandraganti

Shiney Chandraganti

Auto-generated profile, based on publicly available information

Shiney Chandraganti

Cornell University 1 Department of Biomedical and Translational Sciences, College of Veterinary Medicine Ithaca, New York

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Although immune checkpoint blockade (ICB) therapy has generated dramatic responses in certain cancer types, breast tumors are largely unresponsive. Epithelial–mesenchymal plasticity (EMP) leads to the assembly of an immunosuppressive tumor microenvironment and drives resistance of breast tumors to immunotherapies. Importantly, targeting CD73 completely sensitizes quasi-mesenchymal (qM) breast tumors to anti-CTLA4 ICB therapy. However, the mechanism(s) of sensitization remained unknown. We demonstrate that targeting CD73 in qM breast tumors sensitizes them to anti-CTLA4 ICB therapy in a CD4+ T cell–dependent manner. Moreover, EMP results in elevated expression of cancer cell–intrinsic CD73 in human triple-negative breast cancers. Given the ability of qM cancer cells to metastasize and resist multiple therapies, these findings can instruct the formation of translational strategies for the treatment of human breast cancers. These findings also bring to the forefront the attractive possibility of utilizing the phenotypic plasticity of cancer cells along with CD73 and CD4+ T cells as a predictive criterion for immunotherapy responsiveness. Significance: EMP enables metastasis and drives resistance to multiple treatment regimens. Our work underscores the possibility of utilizing CD4+ T cells, CD73, and cancer plasticity as predictive criteria for responsiveness to immunotherapy.

13 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Although immune checkpoint blockade therapy has generated dramatic responses in certain cancer types, breast tumors are largely unresponsive. Epithelial-mesenchymal plasticity leads to the assembly of an immunosuppressive tumor microenvironment and drives resistance of breast tumors to immunotherapies. Importantly, targeting CD73 completely sensitizes quasi-mesenchymal breast tumors to anti-CTLA4 immune checkpoint blockade therapy. However, the mechanism(s) of sensitization remained unknown. We demonstrate that targeting CD73 in quasi-mesenchymal breast tumors sensitizes them to anti-CTLA4 immune checkpoint blockade therapy in a CD4 + T-cell dependent manner. Moreover, epithelial-mesenchymal plasticity results in elevated expression of cancer cell-intrinsic CD73 in human triple negative breast cancers. Given the ability of quasi-mesenchymal cancer cells to metastasize and resist multiple therapies, these findings can instruct the formation of novel translational strategies for the treatment of human breast cancers. These findings also bring to the forefront the attractive possibility of utilizing the phenotypic plasticity of cancer cells along with CD73 and CD4 + T-cells as a predictive criterion for immunotherapy responsiveness. Teaser: Targeting CD73 sensitizes breast cancer cells with mesenchymal traits to anti-CTLA4 therapy in a CD4 + T-cell dependent manner.

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Supplementary Figure S8. CD73 expression on human breast cancer patient samples.

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Supplementary Figure S3. Targeting CD73 sensitizes quasi-mesenchymal tumors to anti-CTLA4 immune checkpoint blockade therapy in a CD4+ T-cell dependent manner.

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
Supplementary Table 1. Genes present in each cluster depicted in Figure 1A

2 June 2026
Verified
Other
Open access
SCShiney Chandraganti
Shiney Chandraganti
CSCaitlyn Sams
Caitlyn Sams
SSSarthak Sahoo
Sarthak Sahoo
BFBrian Feng
Brian Feng
IOIsabel O’COnnell
Isabel O’COnnell
ADAnushka D. Dongre
Anushka D. Dongre
CD4+ T cells drive sensitization of qM tumors lacking CD73 to anti-CTLA4 ICB. A, Schema and tumor kinetics for sgCD73 tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. B, Schema and tumor kinetics for sgCD73 tumors propagated in WT or CD4-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. C, Schema and tumor kinetics for sgCD73 tumors propagated in WT or MHC-II-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. D, Schema and tumor kinetics for SnailHI qM tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. E, Schema and tumor kinetics for SnailHI qM tumors propagated in WT or CD4-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. F–I, Flow cytometry analysis for (F and H) IFNγ and (G and I) T-BET expression on CD4+ T cells as determined by flow cytometry from SnailHI qM control or sgCD73 tumor-bearing mice treated with the indicated antibodies. Tumors were harvested at 2 weeks (F and G) or 4 weeks (H and I) after treatment. Data represent three independent experiments in which n = 3–8 for each group. A–E, Data represent the SEM, two-way ANOVA, **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. F–I, Data represent the SEM, two-way ANOVA, with Tukey's multiple comparisons test *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.